Increased YKL-40 levels are linked with disease severity of initially diagnosed Graves’ disease

Figures & data

Table 1. Demographic characteristics of enrolled participants.

Variables	Graves’ disease Patients(n=142)	Healthy Controls(n=137)	P value
Age(Y)	40.4±10.1	41.3±9.8	0.315
Gender(M/F)	50/92	53/84	0.548
BMI(kg/m^2)	21.4±2.6	23.2±2.4	<0.001
SBP(mmHg)	125±12	123±10	0.078
DBP(mmHg)	78±7	72±6	<0.001
FT3(pmol/L)	14.53(9.70–19.19)	4.67(4.00–5.69)	<0.001
FT4(pmol/L)	44.82(30.29–55.12)	16.29(14.27–18.41)	<0.001
TSH(μIU/mL)	0.024(0.005–0.044)	2.541(1.560–3.388)	<0.001
TRAb(IU/mL)	29.29(21.32–65.55)	3.12(0.71–5.69)	<0.001
YKL-40(pg/mL)	606.1±149.8	397.4±95.1	<0.001

Figure 1. A. Comparison of serum YKL-40 levels between GD patients and healthy control B. Correlation of serum YKL-40 levels with serum FT3 levels C. Correlation of serum YKL-40 levels with serum FT4 levels D. Correlation of serum YKL-40 levels with serum TSH levels.

Figure 2. A. Comparison of serum YKL-40 levels between among patients with different goiter degrees B. Correlation of serum YKL-40 levels with goiter degree.

Figure 3. A. ROC curve analysis of serum YKL-40 levels with regard to goiter degree 0 v 1 B. ROC curve analysis of serum YKL-40 levels with regard to goiter degree 1 vs 2 C. ROC curve analysis of serum YKL-40 levels with regard to goiter degree 2 vs 3.

Figure 4. A. Correlation of serum YKL-40 levels with average STV in GD patients B. Correlation of serum YKL-40 levels with average TBF in GD patients.

Table 2. Clinical parameters of the GD patients after methimazole administration.

Variables	Before treatment (n=55)	After treatment(n=55)
Age(Y)	40.4±10.1	40.4±10.1
Gender(M/F)	20/35	20/35
Weight	55.3±6.7	57.2±7.4**
BMI(kg/m^2)	21.5±2.3	22.2±2.4
SBP(mmHg)	122±9	120±8
DBP(mmHg)	77±8	75±7
FT3(pmol/L)	14.21(9.88–18.34)	9.65(5.08–13.23)***
FT4(pmol/L)	43.33(31.26–54.10)	25.33(20.27–31.11)***
TSH(μIU/mL)	0.015(0.005–0.029)	0.193(0.099–0.418)***
YKL-40(pg/mL)	593.1±123.8	412.5±100.2***

**P<0.01 ***P<0.001.